Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial

mAbs

Volumn 10, Issue 6, 2018, Pages 934-943

  Park, Won ^a   Božić Majstorović, Ljubinka ^b   Milakovic, Dragana ^b   Berrocal Kasay, Alfredo ^c   El Khouri, Elias Chalouhi ^d   Irazoque Palazuelos, Fedra ^e   Molina, Francisco Fidencio Cons ^f   Shesternya, Pavel ^g   Miranda, Pedro ^h   Medina Rodriguez, Francisco G ⁱ   Wiland, Piotr ^j   Jeka, Slawomir ^k   Chavez Corrales, Jose ^l   Garmish, Olena ^m   Linde, Thomas ⁿ   Rekalov, Dmytro ^o   Hrycaj, Pawel ^p   Krause, Andreas ^q   Fomina, Natalia ^r   Piura, Olena ^s   Abello Banfi, Mauricio ^t   Suh, Chang Hee ^u   Shim, Seung Cheol ^v   Lee, Sang Joon ^w   Lee, Sung Young ^w   Kim, Sung Hwan ^w   Yoo, Dae Hyun ^x   more..

^a Inha University School of Medicine   (South Korea)

^b Center of Legal Medicine of Republic of Srpska   (Bosnia and Herzegovina)

^c ABK Reuma SRL Medicentro Biociencias   (Peru)

^d Clinica Internacional   (Peru)

^e Centro de Investigación y Tratamiento Reumatológico S C   (Mexico)

^f Centro de Investigacion en Artritis y Osteoporosis   (Mexico)

^g KRASNOYARSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^h Centro de Estudios Reumatologicos   (Chile)

ⁱ UNIVERSIDAD LA SALLE   (Mexico)

^j WROCLAW MEDICAL UNIVERSITY   (Poland)

^k NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^l Clinica San Borja   (Peru)

^m Ukranian Strazhesko Institute of Cardiology   (Ukraine)

ⁿ MVZ für Rheumatologie und Autoimmundiagnostik   (Germany)

^o ZAPORIZHZHIA STATE MEDICAL UNIVERSITY   (Ukraine)

^p POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^q MARTIN LUTHER KRANKENHAUS   (Germany)

^r Kemerovo Regional Clinical Psychiatric Hospital   (Russian Federation)

^s Kyiv Clinic Hospital No3   (Ukraine)

^t Centro de Fracturas   (Colombia)

^u Ajou University School of Medicine   (South Korea)

^v Chungnam National University College of Medicine   (South Korea)

^w Celltrion Inc   (South Korea)

^x Hanyang University Hospital for Rheumatic Diseases   (South Korea)

more..

Author keywords

biosimilar; CT P10; equivalence; rheumatoid arthritis; Rituximab

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; RITUXIMAB; ANTIRHEUMATIC AGENT; BIOSIMILAR AGENT; CT-P10; MONOCLONAL ANTIBODY;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOGENICITY; INFLUENZA; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS; THROAT IRRITATION; UPPER RESPIRATORY TRACT INFECTION; CHEMICALLY INDUCED; CLINICAL TRIAL; INFECTION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; THERAPEUTIC EQUIVALENCE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; BIOSIMILAR PHARMACEUTICALS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFECTION; MALE; MIDDLE AGED; RITUXIMAB; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 85050005180     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2018.1487912     Document Type: Article

References (24)

1. European Medicines Agency. MabThera (rituximab) [Summary of Product Characteristics]. 2018. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf
2. Marston B, Palanichamy A, Anolik JH., B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2010;22(3):307–315. doi:10.1097/BOR.0b013e3283369cb8
3. Panayi GS. B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? Rheumatology (Oxford). 2005;44 (Suppl 2):ii3–ii7. doi:10.1093/rheumatology/keh616
4. Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am Journal Transplant. 2006;6(5 Part 1):859–866. doi:10.1111/j.1600-6143.2006.01288.x
5. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester G-R, Cravets MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793–2806. doi:10.1002/art.22025
6. Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572–2581. doi:10.1056/NEJMoa032534
7. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollehoven RF, Li NF, Agarwal S, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390–1400. doi:10.1002/art.21778
8. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf
9. U.S. Food and Drugs Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. 2015. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
10. Yoo DH, Suh C-H, Shim SC, Jeka S, Cons Molina FF, Hrycaj P, Wiland P, Lee EY, Medina-Rodriguez FG, Shesternya P, et al. A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(3):566–570. doi:10.1136/annrheumdis-2016-209540
11. Park W, Suh C-H, Shim SC, Cons Molina FF, Jeka S, Medina-Rodriguez FG, Hrycaj P, Wiland P, Lee EY, Shesternya P, et al. Efficacy and safety of switching from innovator rituximab to biosimilar CT-P10 compared with continued treatment with CT-P10: results of a 56-week open-label study in patients with rheumatoid arthritis. BioDrugs. 2017;31(4):369–377. doi:10.1007/s40259-017-0233-6
12. Yoo DH, Suh C-H, Shim SC, Jeka S, Cons Molina FF, Hrycaj P, Wiland P, Lee EY, Medina-Rodriguez FG, Shesternya P, et al. Efficacy, safety and pharmacokinetics of up to two courses of the rituximab biosimilar CT-P10 versus innovator rituximab in patients with rheumatoid arthritis: results up to week 72 of a phase I randomized controlled trial. BioDrugs. 2017;31(4):357–367. doi:10.1007/s40259-017-0232-7
13. Yoo DH, Park W, Suh C-H, Shim SC, Jeka S, Cons Molina FF, Hrycaj P, Spieler W, Wiland P, Brzezicki J. Efficacy and safety of rituximab biosimilar candidate (CTP-10) and innovator rituximab in patients with rheumatoid arthritis: results from phase I randomized controlled trial over 72 weeks. 2015 ACR/ARHP annual meeting: abstract number 2058. http://acrabstracts.org/abstract/efficacy-and-safety-of-rituximab-biosimilar-candidate-ct-p10-and-innovator-rituximab-in-patients-with-rheumatoid-arthritis-results-from-phase-i-randomized-controlled-trial-over-72-weeks/
14. Yoo DH, Park W, Suh C-H, Shim SC, Cons Molina FF, Jeka S, Brzezicki J, Medina-Rodriguez FG, Hrycaj P, Wiland P. Efficacy and safety of switched CT-P10 from innovator rituximab compared to those of maintained CT-P10 in patients with rheumatoid arthritis up to 56 weeks. 2015 ACR/ARHP annual meeting: abstract number 1675. http://acrabstracts.org/abstract/efficacy-and-safety-of-switched-ct-p10-from-innovator-rituximab-compared-to-those-of-maintained-ct-p10-in-patients-with-rheumatoid-arthritis-up-to-56-weeks/
15. Kim WS, Buske C, Ogura M, Jurczak W, Sancho JM, Zhavrid E, Kim JS, Hernández-Rivas JÁ, Prokharau A, Vasilica M, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol. 2017;4(8):e362–e373. doi:10.1016/S2352-3026(17)30120-5
16. Chen K, Page JG, Schwartz AM, Lee TN, DeWall SL, Sikkema DJ, Wang C. False-positive immunogenicity responses are caused by CD20+ B cell membrane fragments in an anti-ofatumumab antibody bridging assay. J Immunol Methods. 2013;394(1–2):22–31. doi:10.1016/j.jim.2013.04.011
17. Amaravadi L, Song A, Myler H, Thway T, Kirshner S, Devanarayan V, Ni YG, Garofolo F, Birnboeck H, Richards S. 2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3–LBA, biomarkers and immunogenicity). Bioanalysis. 2015;7(24):3107–3124 doi:10.4155/bio.15.226
18. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, Latinis K, Abud-Mendoza C, Szczepanski LJ, Roschmann RA, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69(9):1629–1635. doi:10.1136/ard.2009.119933
19. Singh JA, Saag KG, Bridges SL, Jr., Akl EA, Bannuru RR, Sullivan MC, Vaysbrot E, McNaughton C, Osani M, Shmerling RH. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2016. 2015;68(1):1–25. doi:10.1002/acr.22783
20. Putrik P, Ramiro S, Kvien TK, Sokka T, Pavlova M, Uhlig T, Boonen A. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198–206. doi:10.1136/annrheumdis-2012-202603
21. Schellekens H, Smolen JS, Dicato M, Rifkin RM. Safety and efficacy of biosimilars in oncology. Lancet Oncol. 2016;17(11):e502–e509. doi:10.1016/S1470-2045(16)30374-6
22. Gulacsi L, Brodszky V, Baji P, Rencz F, Pentek M. The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries. Adv Ther. 2017;34(5):1128–1144. doi:10.1007/s12325-017-0522-y
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheumat. 1988;31(3):315–324. doi:10.1002/art.1780310302
24. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Clin Exp Rheumatol. 2005;23(5 Suppl 39):S93–S99